Newly Diagnosed Glioblastoma in Elderly Patients.

ABSTRACT:

Purpose of review

Elderly patients with newly diagnosed glioblastoma (eGBM) carry a worse prognosis compared with their younger counterparts. eGBM garners special attention due to the unique challenges, including increased treatment-associated toxicity, less relative benefit from aggressive therapy, medical comorbidities, and immunosuppression. The pivotal GBM trials excluded patients > 70 years old and the optimal treatment approach remains unsettled for eGBM. In this review, we analyze the historical evidence-based data for treating eGBM and discuss the future direction for managing this vulnerable population.

Recent findings

Treatment for eGBM continues to evolve. Therapy choice is guided by performance status and presence of O6-methylguanine-DNA-methyltransferase (MGMT)

SUBMITTER: Yuen CA 

PROVIDER: S-EPMC8817659 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature